RAPGEF2

Across TCGA pan-cancer cohorts, RAPGEF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAPGEF2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAPGEF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAPGEF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where RAPGEF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.783	0.374	<.001	84	view →
LSCC	DFS	Tertile	II,III,IV	0.394	0.785	.015	16	view →
LUAD	OS	Median	All	0.598	0.882	.017	14	view →
GBM	DFS	Median	All	0.811	0.681	.027	3	view →
PDAC	OS	Tertile	II,III,IV	0.423	0.558	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAPGEF2–CCRCC (DFS)

Open the CCRCC breakdown →